Cagrilintide plus semaglutide for obesity management

Lancet. 2021 May 8;397(10286):1687-1689. doi: 10.1016/S0140-6736(21)00944-2. Epub 2021 Apr 22.

Authors

Sara Becerril¹, Gema Frühbeck²

Affiliations

¹ Metabolic Research Laboratory, Department of Endocrinology & Nutrition, Clínica Universidad de Navarra, University of Navarra, IdiSNA, CIBEROBN, 31008 Pamplona, Spain.
² Metabolic Research Laboratory, Department of Endocrinology & Nutrition, Clínica Universidad de Navarra, University of Navarra, IdiSNA, CIBEROBN, 31008 Pamplona, Spain. Electronic address: gfruhbeck@unav.es.

PMID: 33894837
DOI: 10.1016/S0140-6736(21)00944-2

No abstract available

Publication types

Comment

MeSH terms

Glucagon-Like Peptides
Humans
Islet Amyloid Polypeptide
Obesity Management*

Substances

Islet Amyloid Polypeptide
semaglutide
Glucagon-Like Peptides
cagrilintide